Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shoreline Biosciences
San Diego, California, United Statesshorelinebio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs). The company won a summary judgment victory against Fate Therapeutics and Whitehead Institute on iPSC generation and use in 2023.
- Therapeutic areas
- OncologyImmunology
- Modalities
- iPSC-derived natural killer (iNK) cell therapiesiPSC-derived macrophage (iMACs) cell therapiescellular immunotherapies
- Industry
- Biotech
02
Partnerships
Kite (a Gilead Company)BeiGeneEditas Medicine
Beyond the preview
Go deeper on Shoreline Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shoreline Biosciences.